Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
1. A method of treating a subject suffering from refractory ER-positive breast cancer, comprising administering to said subject a selective androgen receptor modulator (SARM) compound represented by a structure of formula VIII or formula IX:
wherein said treating does not include preventing.
2. The method of claim 1 , wherein said refractory ER-positive breast cancer is a breast cancer that has failed selective estrogen receptor modulator (tamoxifen, toremifene), aromatase inhibitor, trastuzumab, ado-trastuzumab emtansine, pertuzumab, lapatinib, exemestane, bevacizumab, and/or fulvestrant treatments.
3. The method of claim 1 , wherein said refractory ER-positive breast cancer is refractory AR-positive ER-positive breast cancer.
4. The method of claim 1 , wherein said refractory ER-positive breast cancer is AR-positive, PR-positive and HER2-negative and wherein the structure is formula IX.
5. The method of claim 1 , wherein said refractory ER-positive breast cancer is AR-positive, PR-negative and HER2-positive.
6. The method of claim 1 , wherein said refractory ER-positive breast cancer is AR-positive, PR-positive and HER2-positive.
7. The method of claim 1 , comprising administering an isomer, a racemic mixture containing a SARM compound, a metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or crystal of said selective androgen receptor modulator, or any combination thereof.
8. The method of claim 7 , wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical product in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical product; orally administering to said subject said pharmaceutical product in a liquid or solid form; or topically applying to said subject said pharmaceutical product.
9. The method of claim 8 , wherein said pharmaceutical product is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.